إعلان
إعلان
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
28.96
USDبرعاية
-0.07
-0.26%
٠٢ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
28.64
-0.32
-1.10%
تقارير أرباح ARQT
النسبة الإيجابية المفاجئة
ARQT تفوق 20 من 24 آخر التقديرات.
83%
التقرير التالي
بيانات التقرير القادم
١٠ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$112.49M
/$0.06
التغير الضمني من Q3 25 (Revenue/ EPS)
+13.37%
/--
التغير الضمني من Q4 24 (Revenue/ EPS)
+57.64%
/-166.67%
Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue
On ٢٨ أكتوبر ٢٠٢٥, ARQT reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.10 USD, resulting in a 158.88% surprise. Revenue reached 99.22 مليون, compared to an expected 88.72 مليون, with a 11.84% difference. The market reacted with a +27.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of 0.06 USD, with revenue projected to reach 112.49 مليون USD, implying an increase of 0.00% EPS, and increase of 13.37% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
What were Arcutis Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of $0.06, beating estimates by 158.88%, and revenue of $99.22M, 11.84% above expectations.
How did the market react to Arcutis Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 27.04%, changed from $19.64 before the earnings release to $24.95 the day after.
When is Arcutis Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ١٠ فبراير ٢٠٢٦.
What are the forecasts for Arcutis Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of $0.06 and revenue of $112.49M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان